UPDATE: Exelixis (EXEL) Falls to Session Low on Cabozantinib and Opdivo Data

September 28, 2016 11:46 AM EDT
Get Alerts EXEL Hot Sheet
Price: $10.89 -2.59%

Rating Summary:
    5 Buy, 4 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 25 | Down: 27 | New: 8
Trade EXEL Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

(Updated - September 28, 2016 11:57 AM, 12.56 PM EDT)

Exelixis (NASDAQ: EXEL) shares dropped Wednesday, falling 20%. The decline was tied to concerns about cabozantinib and Opdivo data and a numerically lower objected response rate vs other drugs combinations in testing.

According to Bloomberg, Stifel analyst Stephen Willey said data precludes comparisons.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot Comments, Momentum Movers, Trader Talk

Related Entities


Add Your Comment